E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with iron deficiency anemia and pulmonary hypertension |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with iron deficiency anemia and pulmonary hypertension |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10022974 |
E.1.2 | Term | Iron deficiency anemia |
E.1.2 | System Organ Class | 100000004851 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10037401 |
E.1.2 | Term | Pulmonary hypertensions |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effects of oral ferric maltol on hemoglobin levels in patients with pulmonary hypertension and anemia caused by iron deficiency |
|
E.2.2 | Secondary objectives of the trial |
To assess the effects of oral ferric maltol on serum ferritin, transferrin saturation, 6 min walking distance, NT-proBNP, right ventricular function (determined by echocardiography) and World Health Organization Functional Class (WHO FC) in patients with pulmonary hypertension and anemia caused by iron deficiency |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signed written informed consent prior to any study-related procedure and willingness to comply with treatment and follow-up procedures 2. Male and female patients ≥18 years at day of inclusion 3. Patients capable of understanding the investigational nature, potential risks and benefits of the clinical trial 4. Patients with a diagnosis of PH confirmed by a (historical) right heart catheterization showing a mean pulmonary artery pressure ≥25 mmHg at rest and stable PH medication for at least 3 months. 5. 6 min walk distance >50 m 6. Mild-to-moderate iron-deficiency anemia as defined by a hemoglobin concentration ≥7 g/dl and <12 g/dl in females or ≥8 g/dl and <13 g/dl in males, and serum ferritin <100 µg/l, or 100-300 µg/l and transferrin saturation <20% at screening 7. Prevention of pregnancy: Women without childbearing potential defined as follows: • at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or • hysterectomy or uterine agenesis or • ≥ 50 years and in postmenopausal state ≥ 1 year or • < 50 years and in postmenopausal state ≥ 1 year with serum FSH > 40 IU/l and serum oestrogen < 30 ng/l or a negative oestrogen test or Women of childbearing potential with a negative ß-HCG pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of four weeks following the last administration of study medication: • correct use of contraception methods. The following are acceptable: hormonal contraceptives (combined oral contraceptives and oestrogen-free pills with desogestrel, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUS) or a barrier method, e.g. condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film, cream or suppository) • true abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception) • sexual relationship only with female partners and/or sterile male partners
|
|
E.4 | Principal exclusion criteria |
1. Active hematological disorders other than iron-deficiency anemia 2. Other medical condition that according to the investigator’s assessment is causing or contributing to anemia 3. Active malignancy 4. Active infectious disease 5. Active bleeding 6. Severe renal insufficiency (glomerular filtration rate <30 ml/min) 7. Severe liver injury as indicated by serum aminotransferases >3 x upper limit of normal or bilirubin levels >50 µmol/l 8. Ongoing oral or intravenous iron supplementation 9. Hemoglobin <7 g/dl in females or <8 g/dl in males at screening 10. Concomitant erythropoietin medication 11. Pregnancy or lactation period 12. Subject has received any investigational medication or any investigational device within 30 days prior to the first dose of study medication or is actively participating in any investigational drug/devices trial, or is scheduled to receive an investigational drug/devices during the course of the study. 13. Known or suspected hypersensitivity to any of the active substances or any excipients of the investigational medicinal product 14. Known haemochromatosis or other iron overload syndromes 15. Patients who have been receiving repeated (>1) blood transfusions during the past 6 months
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Change in hemoglobin level from baseline to week 12 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Change in hemoglobin from baseline to week 6 • Change in serum ferritin levels and transferrin saturation from baseline to week 6 and 12 • Change in 6 min walking distance from baseline to week 12 • Change in serum NT-proBNP from baseline to weeks 6 and 12 • Change in echocardiographic markers of right ventricular function (right atrial area, right ventricular diameter, fractional area change, tricuspid annular plane systolic excursion) from baseline to week 12 in patients with pulmonary hypertension and anemia caused by iron deficiency. • Change in WHO FC from baseline to week 6 and week 12
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
week 6 week 6 and 12 week 12 week 6 and 12 week 12 week 6 and 12 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 19 |
E.8.9.1 | In the Member State concerned days | |